Johnson & Johnson: Influenza, Human trials

The registry lists 31 Influenza, Human studies with Johnson & Johnson as lead sponsor. 0 are open to participants now and 16 have results posted.

Phase 1 7Phase 2 5Phase 3 11Phase 4 4No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• A Study of Ad26.COV2.S and Influenza Vaccines in Healthy AdultsCompletedNCT05091307Phase 3Results posted
• A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and OlderCompletedNCT05071313Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Non-Hospitalized Participants With Influenza A Infection Who Are at Risk of Developing ComplicationsTerminatedNCT03381196Phase 3Results posted
• A Study to Evaluate the Efficacy and Safety of Pimodivir in Combination With the Standard-of-Care Treatment in Adolescent, Adult, and Elderly Hospitalized Participants With Influenza A InfectionTerminatedNCT03376321Phase 3Results posted
• A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable HealthCompletedNCT03339713Phase 2Results posted
• A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A InfectionCompletedNCT02532283Phase 2Results posted
• Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza StrainsCompletedNCT01631110Phase 3Results posted
• Re-licensing Study to Assess Virosomal Influenza Vaccine Formulated With WHO Recommended Influenza StrainsCompletedNCT01631071Not applicableResults posted
• Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two Different SuppliersCompletedNCT01412281Phase 3Results posted
• Study of Quinvaxem for Vaccination Against Diphtheria, Pertussis, Tetanus, Hepatitis B and Diseases Caused by Haemophilus Influenzae Type BCompletedNCT01362517Phase 3Results posted
• Comparison of the Efficacy of Inflexal V With a Commercially Available Influenza Vaccine in Young ChildrenCompletedNCT01310400Phase 3Results posted
• A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2010/2011 Influenza Virus Strains for the Northern HemisphereCompletedNCT01306305Phase 4Results posted
• A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2009/2010 Influenza Virus Strains for the Northern HemisphereCompletedNCT01306253Phase 4Results posted
• A Re-licensing Study to Assess the Efficacy of Inflexal V Formulated With WHO Recommended 2008/2009 Influenza Virus Strains for the Northern HemisphereCompletedNCT01303510Phase 4Results posted
• Immunogenicity and Safety of a Single 0.5 mL Dose of Inflexal V With a 0.25 mL 2-dose Regimen of Inflexal VCompletedNCT01229397Phase 3Results posted
• Immunogenicity and Safety Study to Assess Influenza Vaccine Formulated With Haemagglutinin (HA) Antigen From Two SuppliersCompletedNCT01229371Phase 3Results posted
• Pre-Approval Access to Pimodivir for the Treatment of Patients With H7N9 Influenza A InfectionNo longer availableNCT03834376
• A Drug-Drug Interaction Study to Evaluate the Effect of AL-794 on the Pharmacokinetics of Oseltamivir and JNJ-63623872CompletedNCT02888327Phase 1
• Idylla IFV-RSV Panel Clinical TestingCompletedNCT02786381
• A Study to Assess the Relative Oral Bioavailability of JNJ-63623872 Administered as Oral Concept Formulations Compared to the Current Tablet FormulationCompletedNCT02659735Phase 1
• A Study of AL-794 to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Doses, and the Antiviral Activity of Multiple Doses in an Influenza Challenge StudyCompletedNCT02588521Phase 1
• Study of Acute Uncomplicated Seasonal Influenza A in Adult SubjectsCompletedNCT02342249Phase 2
• Safety, Tolerability, and Immunogenicity Study of a Cell-based Virosomal Influenza Vaccine in Healthy AdultsCompletedNCT02148328Phase 1
• Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza InfectionWithdrawnNCT01992276Phase 2
• Evaluation of the Protective Efficacy and Safety of CR8020 in an Influenza ChallengeCompletedNCT01938352Phase 2
• Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)CompletedNCT01893177Phase 3
• Evaluation of Viral Shedding Patterns and Clinical Outcomes of Influenza PatientsCompletedNCT01839760
• Assessment of CR8020, a Monoclonal Antibody Against Influenza A VirusesCompletedNCT01756950Phase 1
• Clinical Study for Safety and Immunogenicity Study of Influenza VaccineCompletedNCT01617239Phase 1
• A Study to Assess Immunogenicity Parameters After Vaccination Against Influenza and to Evaluate How These Parameters Change During the Influenza SeasonCompletedNCT01457027Phase 4
• Assessment of CR6261, a Monoclonal Antibody Against the Influenza A VirusCompletedNCT01406418Phase 1